

Representative Legal Matters

Michal Berkner

- Advising Baylis Medical on its USD 1.75 billion sale to Boston Scientific.
- Advising VectivBio on its USD 1.2 billion sale to Ironwood.
- Advising Therachon on its USD 900 million sale to Pfizer.
- Advising Zoll on its USD 583 million acquisition of Itamar Medical.
- Advising Bavarian Nordic on its USD 380 million acquisition of Emergent's travel health business.
- Advising Eagle Pharma on its USD 104 million scheme of arrangement to acquire Acacia Pharma.
- Advising RedX Pharma on its proposed reverse merger and scheme of arrangement with Jounce Therapeutics.
- Advising Anchiano Therapeutics on its reverse merger with Chemomab Therapeutics.
- Advising Alvotech, Oculis and BioTE on business combinations and Nasdaq listings.
- Advising Feedzai, Exscentia, Content Square, Cision Technologies, Clyde Space, Luna Innovations, Hipcamp and other tech companies on multiple transactions.
- Advising Nokia Corporation on its USD 17 billion acquisition of Alcatel-Lucent, USD 1.2 billion acquisition of Motorola's wireless network infrastructure, acquisition of Panasonic Systems Networks and joint venture with China Huaxin Telecom.
- Advising DSV on its USD 1.3 billion acquisition of UTi Worldwide.
- Advising Alfa-Access Renova on its USD 56 billion sale of TNK-BP to Rosneft.
- Advising Dentsply on its USD 1.8 billion acquisition of Astra Tech from AstraZeneca.
- Advising Basell Polyolefins on its USD 22 billion acquisition of Lyondell Chemical.
- Advising Fresenius on its USD 1.6 billion acquisition of APP Pharmaceuticals.
- Advising Samsonite on its USD 1.7 billion sale to CVC Capital.
- Advising SCOR on its USD 2.5 billion unsolicited takeover of Converium.
- Advising Arcelor on its USD 33.8 billion merger with Mittal Steel.
- Advising Goldman Sachs, Morgan Stanley, JPM, Citigroup and other investment banks as financial advisers on numerous cross-border transactions.